Introduction
============

*Staphylococcus aureus* is part of the commensal microorganisms in humans and approximately 20% of healthy individuals are carriers ([@B9]). Although *S. aureus* is not always pathogenic, it is a major cause of a wide range of human diseases, especially skin and soft-tissue infections. *S. aureus* infections are increasingly difficult to eradicate due to the emergence of antimicrobial resistance. In fact, infections by *S. aureus* were well controlled by methicillin up until the emergence of methicillin resistance *S. aureus* ([@B12]). Although vancomycin has been the most reliable and effective therapeutic agent against MRSA infections, an alarming emergence of vancomycin-resistant *S. aureus* strains have recently been reported in many countries such as in Iran, Europe, United States ([@B18]; [@B1]; [@B7]). At the same time, the discovery and development of novel and efficient antibiotics has been significantly decreased. In the battle against rapidly emerging bacterial resistance, rational approaches to use existing antibiotics could be more efficient than discovery of new antibiotics.

Bacitracin is a polypeptide antibiotic produced by stains of *Bacillus licheniformis* and *Bacillus subtilis* and has been clinically used for staphylococcal (such as *S. aureus*) infections since the late 1940s ([@B13]). Bacitracin functions as an inhibitor of cell wall biosynthesis through its binding to the undecaprenyl pyrophosphate ([@B31]). The combination of bacitracin with other antibiotics has been efficient to be used as a topical agent ([@B36]). In the United States, ophthalmic ointments containing bacitracin, polymyxin B and neomycin have been shown to eradicate coagulase-negative staphylococci (CNS) from the human skin surface and the underlying stratum corneum as well as preventing repopulation with resident flora ([@B11]). Whether other polymyxin has similar effects like polymyxin B is unknown.

Colistin is one of the polymyxins, known as polymyxin E. Colistin is effective against most Gram-negative bacilli, and especially effective to treat infections caused by multi-drug-resistant Gram-negative bacteria (MDR-GNB) owing to its favorable properties of rapid bacterial killing, and an associated slow development of resistance ([@B16]). Colistin is able to bind lipopolysaccharide (LPS) ([@B35]). Colistin kills Gram-negative bacteria mainly through disruption of outer membrane integrity of bacteria resulting from binding of the antibiotic with LPS and displacing of divalent cations ([@B40]).

Several studies have claimed that the combination therapy of colistin and other antibiotics are more efficient than a single antibiotic therapy to treat serious infections. For example, [@B29] reported that combination of colistin and imipenem was synergistic (50% of isolates) or indifferent (50%) against colistin-susceptible blaVIM-1-type metallo-β-lactamase-producing (MBL) *K. pneumoniae* strains, while it was antagonistic (55.6%) and rarely synergistic (11%) against colistin-resistant strains. In another study, sub-inhibitory concentrations of meropenem (0.06--8 mg/L) and colistin (0.12--1 mg/L) were synergistic against 13 out of 51 *P. aeruginosa* isolates at 24 h, while the combination of meropenem (0.03--64 mg/L) and colistin (0.06--8 mg/L) showed synergy against *A. baumannii* isolates ([@B25]). [@B27] evaluated the effectiveness of the combination of CMS (colistin methanesulfonate) and rifampicin in 10 patients with ventilator-associated pneumonia caused by carbapenem-resistant (only susceptible to colistin) *A. baumannii* strains and found that seven out of 10 patients benefited from the combination therapy ([@B27]). Recently, it has been shown that colistin potentiated the activity of drugs such as isoniazid and amikacin *in vitro* against *Mycobacterium tuberculosis* ([@B2]). Owing to its increasing use and reported efficacy in combination therapy against a variety of bacterial infections, in this study we wanted to investigate whether the antibacterial effect of bacitracin against *S. aureus* could be enhanced by colistin.

Materials and Methods {#s1}
=====================

Bacteria Strains, Growth Conditions, and Resistance Detection
-------------------------------------------------------------

*S. aureus* BA01611 (MRSA, [@B38]), *S. aureus* BA01511 (from our laboratory), *S. aureus* WS1 ([@B17]), *S. aureus* RN4220, *S. aureus* Mu50 (MRSA), *S. aureus* ATCC 29213 and *S. aureus* Newman were used in this study. The Mueller-Hinton (MH) medium was used for the growth of *S. aureus*. MICs for antimicrobial agents were determined by using an agar dilution method recommended by the [@B6]. The MIC was determined as the lowest concentration at which growth was completely inhibited. Determination of MICs was repeated three times.

Susceptibility Screen
---------------------

The susceptibility screen assay was performed as described previously ([@B10]). *S. aureus* strains were grown overnight and the cultures were adjusted to subsamples of 5 × 10^5^ CFU/mL in the warm MH broth. Colistin sodium sulfate (Sigma) was added as an inducer at the concentrations of 1/2 MIC (64 μg/mL) for each strain. After 90 min at 37°C with shaking at 180 rpm, 10 μL aliquots of the cultures were spotted on MH agar plates containing bacitracin (Sigma) at a concentration of 1/2 MIC (64 μg/mL). The plates were incubated overnight at 37°C before checking the bacterial growth. Each experiment was repeated three times.

Determination of the *in vitro* Effects of Combinations of Bacitracin and Colistin
----------------------------------------------------------------------------------

The antimicrobial combination assays were conducted with bacitracin plus colistin by using the broth microdilution checkerboard technique ([@B19]). The test was performed using 96-well microtiter plates containing colistin and bacitracin in twofold serial concentrations. Bacterial suspensions were prepared to yield a final inocula of ∼5 × 10^5^ CFU/mL. Plates were read after overnight incubation at 37°C. Fractional Inhibitory Concentration (FIC) Index was calculated according to the formulas: FIC~bacitracin~ = MIC~bacitracin+colistin~/MIC~bacitracin~, FIC~colistin~ = MIC~bacitracin+colistin~/ MIC~colistin~, FIC Index = FIC~bacitracin~+ FIC~colistin~. FIC Index values were interpreted according to [@B23]: synergy (FIC Index ≤ 0.5); partial synergy (FIC Index \> 0.5 to ≤ 0.75); additivity (FIC Index \> 0.75 to ≤ 1); no interaction (indifference) (FIC Index \> 1 to ≤ 4) and antagonism (FIC Index \> 4.0) ([@B23]). Each experiment was repeated three times.

The Time-Kill Assay
-------------------

The time-killing curve assays were performed in triplicate to study the effect of the combination of bacitracin and colistin on *S. aureus* BA01611 growth as previously described by [@B23] with minor modifications ([@B23]). A single bacterial colony was added to 2 mL of the MHB and grown overnight at 37°C with shaking at 180 rpm. The overnight culture was diluted with pre-warmed MHB to obtain a starting inoculum of approximately 5 × 10^5^ CFU/mL. The *S. aureus* BA01611 strain was exposed to colistin at the concentrations of 0 or 1/2 MIC (64 μg/mL) in the presence or absence of 1/2 MIC (64 μg/mL, except 8 μg/mL for *S. aureus* BA01511) bacitracin. Samples were taken at 0, 2, 4, 6, 8, 16, and 24 h, serially diluted, spread on drug-free plates, and incubated at 37°C for 24 h before counting the colonies. Each experiment was repeated three times.

Autolysis Assay
---------------

The autolysis assay was performed as described previously ([@B20]). *S. aureus* BA01611 isolate was grown overnight and diluted in the pre-warmed MH broth and grown to the mid-exponential phase. The cells were exposed to 64 μg/mL colistin while the control was not exposed to colistin. After 1 h of exposure, the cultured cells were washed twice in cold sterile distilled water and re-suspended in the same volume of 0.05 M Tris-HCl, pH 7.2, containing 0.05% Triton X-100. Cells were incubated at 30°C, and the OD~600~ was measured every 30 min. Data are expressed as the percent loss of OD~600~ at the indicated times compared to findings at time zero. Each experiment was repeated three times.

Determination of Whole-Cell Surface Charges
-------------------------------------------

The determination of whole-cell surface charges was performed as described previously ([@B20]). After culturing overnight, *S. aureus* BA01611 was diluted in the pre-warmed MH broth to ensure continued exponential growth during treatment. Cells were treated with and without colistin for 1, 2, and 4 h before harvesting at the mid-exponential phase. After washing twice by centrifugation in 20 mM MOPS buffer, pH 7, the cells were re-suspended in the neutral pH MOPS buffer to a final OD~600~ of 0.6 before adding the positively charged cytochrome c (Sigma) at a concentration of 0.125 mg/mL. The mixture was incubated at room temperature for 10 min before centrifugation and the amount of unbound cationic cytochrome c in the supernatant was quantified photometrically at 530 nm. Each experiment was repeated three times.

Ion Leakage
-----------

The leakage of ions was performed as described previously ([@B21]). Bacterial cells (*S. aureus* BA01611) were incubated for 24 h and then diluted in pre-warmed MH broth to ensure continued exponential growth during treatment. Cells were exposed to colistin (64 μg/mL) for 1 and 2 h. The bacterial cells without colistin exposure were used as a control. Bacterial cells were harvested by centrifugation at 12,000 × *g* for 15 min and washed twice with cold deionized water. The cells were then adjusted to the same OD~600~ and the dry weight was determined followed by digestion in a HNO~3~/H~2~O~2~ solution at 100°C for 24 h. After dissolution, the cells were centrifuged and the supernatant were recovered and assayed for total mineral content of cells (K^+^, Na^+^, Ca^2+^, Mg^2+^, Zn^2+^, Cu^2+^, and Mn^2+^) by ICP Mass Spectrometers (Varian 810/820-MS). Each experiment was repeated three times.

Scanning Electron Microscope (SEM)
----------------------------------

SEM were performed as described previously ([@B39]). *S. aureus* BA01611 cells were treated with 1/2 MIC (64 μg/mL) colistin and/or 1/2 MIC (64 μg/mL, except 8 μg/mL for *S. aureus* BA01511) bacitracin for 1 h and 2 h. Untreated controls were also prepared. The bacterial cells were collected via centrifugation at 10,000 × *g* and then the pellet formed was washed with PBS for three times. Fixation was done by suspending the bacterial cells into 0.25% of glutaraldehyde solution (in PBS, pH 7.0) and then incubated at room temperature for 1 h before collecting the fixed bacterial pellet. Dehydration of the bacterial cells was done by washing the pellets with ethanol at different concentrations up to 100%. After the critical-point drying, the bacterial cells were observed with a field-emission scanning electron microscopy (FE-SEM; FEI Inspect F50).

Results
=======

Existence of the Effect of the Combination of Colistin and Bacitracin Against *S. aureus*
-----------------------------------------------------------------------------------------

In order to determine whether colistin would induce *S. aureus* susceptibility to bacitracin, seven *S. aureus* strains were screened. *S. aureus* strains were first treated with colistin at a concentration of 1/2 MIC (64 μg/mL), then 10 μL aliquots of the cultures were spotted on freshly prepared MH agar plates containing bacitracin at a concentration of 1/2 MIC (64 μg/mL, except 8 μg/mL for *S. aureus* BA01511). As shown in Figure [1](#F1){ref-type="fig"}, such treatments inhibited the growth of all seven strains, suggesting that colistin could induce *S. aureus* susceptibility to bacitracin.

![The ability of seven *S. aureus* stains to form colonies at a concentration of 1/2 MIC (64 μg/mL, except 8 μg/mL for *S. aureus* BA01511) bacitracin was assayed after pre-exposure to colistin for 90 min. **(A)** *S. aureus* BA01611 isolate was also incubated on MHA without bacitracin, **(B)** *S. aureus* BA01511, **(C)** *S. aureus* WS1, **(D)** *S. aureus* RN4220, **(E)** *S. aureus* Mu50, **(F)** *S. aureus* ATCC 29213, and **(G)** *S. aureus* Newman.](fmicb-09-02805-g001){#F1}

Next, a checkerboard assay was performed for each *S. aureus* strain, using several concentrations ranging from below the MIC to 2x MIC. As shown in Figure [2](#F2){ref-type="fig"}. synergy as indicated by FIC index ≤ 0.5 was obvious in six out of seven strains, while *S. aureus* WS1 showed a partial synergy with the FIC index equal to 0.53125.

![Results from the checkerboard test. Shading indicates visible growth. The Fractional Inhibitory Concentration (FIC) was calculated. **(A)** *S. aureus* BA01611 (FIC index = 0.3125), **(B)** *S. aureus* BA01511 (FIC index = 0.2500), **(C)** *S. aureus* WS1 (FIC index = 0.53125), **(D)** *S. aureus* RN4220 (FIC index = 0.375), **(E)** *S. aureus* Mu50 (FIC index = 0.5000), **(F)** *S. aureus* ATCC 29213 (FIC index = 0.3750) and **(G)** *S. aureus* Newman (FIC index = 0.3750).](fmicb-09-02805-g002){#F2}

Furthermore, a time-kill analysis was carried out with one MRSA strain *S. aureus* BA01611. As shown in Figure [3](#F3){ref-type="fig"}, colistin alone or bacitracin alone did not lead to cell growth inhibition after 24 h incubation compared to the control. The combination of colistin and bacitracin resulted in a \> 2log~10~ decrease compared to the control after the 24 h incubation period, indicating that the efficiency of the combination of colistin and bacitracin against *S. aureus* strains.

![Time-kill curves of colistin and/or bacitracin against *S. aureus* BA01611. Data are presented as means ± standard deviations. The statistical analysis was performed using a one-way analysis of variance (ANOVA) with the least significant difference (LSD) test. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 in comparison with the control group.](fmicb-09-02805-g003){#F3}

Autolytic Activity Is Increased in *S. aureus* Treated With Colistin
--------------------------------------------------------------------

To investigate how colistin induced *S. aureus* susceptibility to bacitracin, a Triton X-100-induced autolytic activity of the BA01611 strain was first measured after exposure to colistin. As shown in Figure [4](#F4){ref-type="fig"}, exposure of *S. aureus* BA01611 to colistin at a concentration of 64 μg/mL increased autolysis in comparison with that of the unexposed strain. Triton lysis profiles differed significantly after 150 min exposure to colistin (0.468 ± 0.0196 vs. 0.403 ± 0.0142 after 150 min: 0.527 ± 0.0073 vs. 0.460 ± 0.0117 after 180 min). The results indicated that the susceptibility to bacitracin after colistin induction could be due to the damaged cell structure.

![Triton X-100 autolysis assay of *S. aureus* BA01611. Cells were grown with or without colistin for 1 h before being washed and resuspended in buffer containing the detergent. Absorbance at 600 nm was determined for 3 h. Autolysis was determined based on the decrease in the optical density over time relative to that at time zero for each sample. Data are presented as means ± standard deviations. The statistical analysis was performed using a one-way analysis of variance (ANOVA) with the least significant difference (LSD) test. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 in comparison with the control group.](fmicb-09-02805-g004){#F4}

Whole-Cell Surface Positive Charge Decreased in *S. aureus* Treated With Colistin
---------------------------------------------------------------------------------

As colistin is known as an important cationic antimicrobial peptide which could displace calcium and magnesium, whether the electrostatic nature of *S. aureus* BA01611 surface was affected by colistin was then determined by adding cationic cytochrome c. As shown in Figure [5](#F5){ref-type="fig"}, bacterial cells treated with colistin had a significantly greater quantity of bound cytochrome c than non-exposed strains. These results implied that colistin might render the bacterial cell membranes less positively charged and make the bacterial cells more susceptible to other antibiotics.

![Detection of cationic cytochrome c binding to whole *S. aureus* BA01611 cells in the presence or absence of colistin. The figure shows the percentage of bound cytochrome c after incubating *S. aureus* BA01611 with colistin for 1, 2, or 4 h. Data are presented as means ± standard deviations. The statistical analysis was performed using a one-way analysis of variance (ANOVA) with the least significant difference (LSD) test. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 in comparison with the control group.](fmicb-09-02805-g005){#F5}

Effects of Colistin on Ions Leakage of *S. aureus*
--------------------------------------------------

To further investigate whether *S. aureus* ions leakage occurred upon colistin exposure, total mineral content of cells (K^+^, Na^+^, Ca^2+^, Mg^2+^, Zn^2+^, Cu^2+^, and Mn^2+^) of *S. aureus* BA01611 was determined by ICP Mass Spectrometers. While exposure to colistin for 1 h did not affect the concentration of the majority of ions, exposure to colistin for 2 h led to significant decrease in concentration of ions: Na^+^ by 63.0%; 86.9% for Mg^2+^; 86.1% for K^+^; 61.1% for Ca^2+^; 85.7% for Mn^2+^; 65.0% for Cu^2+^ and 80.7% for Zn^2+^ (Figure [6](#F6){ref-type="fig"}).

![Ion leakages when *S. aureus* BA01611 was exposed to colistin for 2 h. The samples were digested in a HNO~3~/H~2~O~2~ solution of 6 mol/L. The total mineral contents of the bacteria were measured by a Varian 810/820-MS ICP Mass Spectrometer. Data are presented as means ± standard deviations. The statistical analysis was performed using a one-way analysis of variance (ANOVA) with the least significant difference (LSD) test. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 in comparison with the control group.](fmicb-09-02805-g006){#F6}

Cell Surface Was Damaged When *S. aureus* Co-treated With Colistin and Bacitracin
---------------------------------------------------------------------------------

In order to further confirm that the affected cell surface was involved in the effect of colistin to increase susceptibility to bacitracin, *S. aureus* BA01611 was exposed to 1/2 MIC (64 μg/mL) colistin in the presence or absence of 1/2 MIC (64 μg/mL, except 8 μg/mL for *S. aureus* BA01511) bacitracin for 1 and 2 h and the structure of the cell surfaces was visualized by SEM. As shown in Figure [7](#F7){ref-type="fig"}, the surfaces of the untreated cells were relatively smooth and continuous with good structural integrity (Figure [7A](#F7){ref-type="fig"}). With the treatment of colistin or bacitracin, grape-like cell clusters were shown and the cell boundaries were faint and unclear (Figures [7B,C](#F7){ref-type="fig"}). In the combined treatment of colistin and bacitracin, the morphology of *S. aureus* changed significantly: many ghost cells with irregular morphology, and irregular and distorted outlines of the cell packets. In addition, the cells and clumps were larger than those with or without the treatment of colistin or bacitracin alone (Figures [7D,E](#F7){ref-type="fig"}).

![SEM images of *S. aureus* BA01611 cells. **(A)** Untreated *S. aureus* BA01611 (control); **(B)** *S. aureus* BA01611 treated with colistin; **(C)** *S. aureus* BA01611 treated with bacitracin; **(D)** *S. aureus* BA01611 treated with both colistin and bacitracin. Arrows indicated partially damaged surface; **(E)** high magnification of *S. aureus* BA01611 treated with both colistin and bacitracin. The cell surface was damaged in multiple locations.](fmicb-09-02805-g007){#F7}

Discussion
==========

The rise of antimicrobial resistance in *S. aureus* is a major challenge in both hospitals and community settings ([@B34]). Currently, 60--90% of *S. aureus* infections are reported to be methicillin-resistant (MRSA), and people with MRSA are estimated to be 64% more likely to die than people with a non-resistant form of the infection ([@B37]). The limited availability of effective therapies against *S. aureus* has increased the quest to discover new treatment options including the development of new antibiotics as well the combination of antibiotics currently in use in clinical practice. In this study, we found that the antibacterial effects of bacitracin against *S.* *aureus* was enhanced by colistin.

Most studies on combination therapy involving colistin have focused on Gram-negative bacteria. For example, colistin combined with nisin A or pediocin PA-1/AcH synergistically inhibited the enterohemorrhagic bacterium *E. coli* O157:H7 ([@B24]). Similarly, several antibiotics such as rifampicin, imipenem, doxycycline, azithromycin, and ciprofloxacin worked synergistically with colistin against *P. aeruginosa* ([@B4]). However, [@B10] discovered that susceptibility of *S. aureus* to vancomycin was reduced by concurrent exposure to colistin. Bacitracin is proposed as one of the most popular topical antibiotics and usually combined with polymyxin B in a number of commercially available ointments and creams that are used on minor cuts and abrasions as well as postsurgical wounds ([@B8]; [@B30]). Additionally, bacitracin was effective against methicillin-resistant *S. aureus* *in vitro* ([@B5]) and *in vivo* ([@B28]). Therefore, combination of bacitracin and colistin could be an alternative for the treatment of *S. aureus* infections. This study explored that possibility *in vitro* and our results showed for the first time that colistin enhanced the inhibitory effect of bacitracin against *S. aureus*. Seven *S. aureus* strains used in this study were resistant to colistin with high MIC values. Generally speaking, Gram-positive bacteria are generally less sensitive to polymyxins than Gram-negative bacteria ([@B33]). The increased susceptibility of *S. aureus* to bacitracin by colistin was confirmed by several assays: the spotted assay, the checkerboard assay and time kill kinetics. Moreover, the damaged and irregular surface of *S. aureus* when co-exposure to colistin and bacitracin confirmed the effectiveness of this combination treatment.

How colistin increased susceptibility of bacitracin against *S. aureus* remains unknown. Because colistin kills Gram-negative bacteria by damaging the bacterial cell membrane and in addition to the synergy observed with other antibiotics against Gram-negative bacteria that has been reportedly linked to this function ([@B4]), the effects of colistin on *S. aureus* cell surface were explored to explain the increased susceptibility to bacitracin. Based on our results, two potential mechanisms were proposed: disruption of the cell surface of *S. aureus* by colistin to increase entry of bacitracin into the cells and enhancement of leakage of divalent ions by colistin to enhance bacitracin antibacterial ability.

Destruction of *S. aureus* surface by colistin was supported by our results. In this study, *S. aureus* BA01611 exposed to colistin had an increased autolysis. In addition, colistin decreased positive charges on *S. aureus* cell surface. This could lead to unstable bacterial cells, as networks of metal cations could influence the rigidity and porosity of the cell wall ([@B26]). Furthermore, observed ion leakage from the bacterial cells after colistin exposure suggested increased *S. aureus* membrane permeability. As reviewed by [@B14], permeabilization of the bacterial membrane by colistin may allow the access of a second drug through the outer membrane into the periplasmic space and the cytoplasm, consequently improving the bactericidal activity against Gram-negative bacteria ([@B14]). Electron microscopic study has also shown the cytoplasmic membrane of Gram-negative bacteria appeared to be damaged and part of the cytoplasmic material released in fibrous forms through the cracks when exposed to colistin ([@B15]). Thus, it is plausible that colistin can also modify cell structure of *S. aureus* and allow more bacitracin to get into the cytoplasm. Such a possibility needs further studies to be confirmed.

The increased susceptibility to bacitracin by colistin may also be due to the rearrangement of electric charges on cell surface, leading to the enhanced efficacy of bacitracin. As described above, *S. aureus* showed a higher negative charge of the cells and reduced cellular concentrations of Ca^2+^, Mn^2+^, Zn^2+^, and Mg^2+^ after being exposed to colistin. Bacitracin affects the biosynthesis of the peptidoglycan of bacterial cell walls by binding very tightly to the long-chain C55-isoprenol pyrophosphate and preventing its recycling ([@B32]). These processes need a divalent metal ion and the antimicrobial activity of bacitracin could be stimulated by various metal ions such as Cu^2+^, Mn^2+^ or Zn^2+^ ([@B31]; [@B22]). In Gram-negative bacteria, the polycationic ring of colistin binds to LPS by displacement, in a competitive fashion, of the calcium (Ca^2+^) and magnesium (Mg^2+^) ions from the phosphate groups of LPS, leading to disruption of the outer membrane and loss of cellular contents and consequently killing the bacterium ([@B3]). We hypothesize that colistin may be capable of modulating the teichoic acid net charge by displacing the divalent cations from the phosphate groups of teichoic acids in the cell surface of *S. aureus* and thus enhancing the inhibitory effect of bacitracin on *S. aureus*.

Conclusion
==========

Our study showed the combination of colistin and bacitracin could be feasible for treating *S. aureus* infections. While colistin has attracted considerable interest as an antibiotic for use against multidrug-resistant Gram-negative bacteria, its potential for Gram-positive bacteria such as *S. aureus* should be further explored.
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